<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns="http://purl.org/rss/1.0/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
<channel rdf:about="http://www.clinsci.org">
<title>Clinical Science</title>
<link>http://www.clinsci.org</link>
<description>Clinical Science RSS Feed</description>
<prism:issn>0143-5221</prism:issn>
<prism:eIssn>1470-8736</prism:eIssn>
<prism:publicationName>Clinical Science</prism:publicationName>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.clinsci.org/cs/123/0273/cs1230273.htm" />
  <rdf:li rdf:resource="http://www.clinsci.org/cs/123/0285/cs1230285.htm" />
  <rdf:li rdf:resource="http://www.clinsci.org/cs/123/0295/cs1230295.htm" />
  <rdf:li rdf:resource="http://www.clinsci.org/cs/123/0307/cs1230307.htm" />
  <rdf:li rdf:resource="http://www.clinsci.org/cs/123/0313/cs1230313.htm" />
  <rdf:li rdf:resource="http://www.clinsci.org/cs/123/0323/cs1230323.htm" />

 </rdf:Seq>
</items>
<image rdf:resource="http://www.clinsci.org/images/cs_Name.gif" />
</channel>
<image rdf:about="http://www.clinsci.org/images/cs_Name.gif">
<title>Clinical Science</title>
<url>http://www.clinsci.org/images/cs_Name.gif</url>
<link>http://www.clinsci.org</link>
</image>
<item rdf:about="http://www.clinsci.org/cs/123/0273/cs1230273.htm">
<title><![CDATA[The intracrine renin-angiotensin system]]></title>
<link>http://www.clinsci.org/cs/123/0273/cs1230273.htm</link>
<description><![CDATA[
<p>The RAS (renin-angiotensin system) is one of the earliest and most extensively studied hormonal systems. The RAS is an atypical hormonal system in several ways. The major bioactive peptide of the system, AngII (angiotensin II), is neither synthesized in nor targets one specific organ. New research has identified additional peptides with important physiological and pathological roles. More peptides also mean newer enzymatic cascades that generate these peptides and more receptors that mediate their function. In addition, completely different roles of components that constitute the RAS have been uncovered, such as that for prorenin via the prorenin receptor. Complexity of the RAS is enhanced further by the presence of sub-systems in tissues, which act in an autocrine/paracrine manner independent of the endocrine system. The RAS seems relevant at the cellular level, wherein individual cells have a complete system, termed the intracellular RAS. Thus, from cells to tissues to the entire organism, the RAS exhibits continuity while maintaining independent control at different levels. The intracellular RAS is a relatively new concept for the RAS. The present review provides a synopsis of the literature on this system in different tissues.</p>]]></description>
<dc:creator>R. Kumar, C. M. Thomas, Q. C. Yong, W. Chen and K. M. Baker</dc:creator>
<dc:date>2012-09-01</dc:date>
<dc:identifier>doi:10.1042/CS20120089</dc:identifier>
<dc:title><![CDATA[The intracrine renin-angiotensin system]]></dc:title>
<dc:publisher>Portland Press Ltd.</dc:publisher>
<prism:publicationDate>2012-09-01</prism:publicationDate>
<prism:section></prism:section>
</item>


<item rdf:about="http://www.clinsci.org/cs/123/0285/cs1230285.htm">
<title><![CDATA[Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chronic kidney disease]]></title>
<link>http://www.clinsci.org/cs/123/0285/cs1230285.htm</link>
<description><![CDATA[
<p>Blockade of the MR (mineralocorticoid receptor) in CKD (chronic kidney disease) reduces LVMI [LV (left ventricular) mass index] and proteinuria. The MR can be activated by aldosterone, cortisol and DOC (deoxycorticosterone). The aim of the present study was to explore the influence of mineralocorticoids on LVMI and proteinuria in patients with CKD. A total of 70 patients with CKD and 30 patients with EH (essential hypertension) were recruited. Patients underwent clinical phenotyping; biochemical assessment and 24&#160;h urinary collection for THAldo (tetrahydroaldosterone), THDOC (tetrahydrodeoxycorticosterone), cortisol metabolites (measured using GC-MS), and urinary electrolytes and protein [QP (proteinuira quantification)]. LVMI was measured using CMRI (cardiac magnetic resonance imaging). Factors that correlated significantly with LVMI and proteinuria were entered into linear regression models. In patients with CKD, significant predictors of LVMI were male gender, SBP (systolic blood pressure), QP, and THAldo and THDOC excretion. Significant independent predictors on multivariate analysis were THDOC excretion, SBP and male gender. In EH, no association was seen between THAldo or THDOC and LVMI; plasma aldosterone concentration was the only significant independent predictor. Significant univariate determinants of proteinuria in patients with CKD were THAldo, THDOC, USod (urinary sodium) and SBP. Only THAldo excretion and SBP were significant multivariate determinants. Using CMRI to determine LVMI we have demonstrated that THDOC is a novel independent predictor of LVMI in patients with CKD, differing from patients with EH. Twenty-four hour THAldo excretion is an independent determinant of proteinuria in patients with CKD. These findings emphasize the importance of MR activation in the pathogenesis of the adverse clinical phenotype in CKD.</p>]]></description>
<dc:creator>E. P. McQuarrie, E. M. Freel, P. B. Mark, R. Fraser, R. K. Patel, H. G. Dargie, J. M. C. Connell and A. G. Jardine</dc:creator>
<dc:date>2012-09-01</dc:date>
<dc:identifier>doi:10.1042/CS20120015</dc:identifier>
<dc:title><![CDATA[Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chronic kidney disease]]></dc:title>
<dc:publisher>Portland Press Ltd.</dc:publisher>
<prism:publicationDate>2012-09-01</prism:publicationDate>
<prism:section></prism:section>
</item>


<item rdf:about="http://www.clinsci.org/cs/123/0295/cs1230295.htm">
<title><![CDATA[2-Methoxy-5-amino-N-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms]]></title>
<link>http://www.clinsci.org/cs/123/0295/cs1230295.htm</link>
<description><![CDATA[
<p>COX-2 (cyclo-oxygenase-2) and PGE<sub>2</sub> (prostaglandin E<sub>2</sub>) play a key role in sustaining CRC (colorectal cancer) cell growth and survival. Indeed, the use of agents targeting the COX-2/PGE<sub>2</sub> axis has been associated with a reduction in the development of CRC in both humans and murine models of colon carcinogenesis. In the present study, we investigated whether 2-methoxy-5-amino-<i>N</i>-hydroxybenzamide (herein termed 2-14), a derivative of mesalamine that inhibits CRC cell growth both <i>in vitro</i> and <i>in vivo</i>, negatively regulates COX-2/PGE<sub>2</sub> expression in CRC cells and assessed whether the 2-14-mediated anti-neoplastic effect is strictly dependent on the inhibition of this pathway. Our results show that 2-14 blocks the growth and enhances the death of HT-115, a CRC cell line overexpressing COX-2, and that these effects associate with inhibition of COX-2 but not COX-1. 2-14 also down-regulates TNF&#945; (tumour necrosis factor &#945;)-induced COX-2&#160;in HT-29 cells as well as COX-2/PGE<sub>2</sub> expression in <i>ex vivo</i> cultures of human CRC explants. Similarly, 2-14 reduces COX-2, but not COX-1,&#160;in tumoural areas developing in a mouse model of CAC (colitis-associated colon cancer). Finally, we show that 2-14 exhibits <i>in vitro</i> and <i>in vivo</i> anti-mitogenic effects in DLD-1, a COX-deficient CRC cell line. Taken together, these results suggest that 2-14 inhibits CRC cell growth through COX-2-dependent and -independent mechanisms.</p>]]></description>
<dc:creator>C. Stolfi, E. Franz&#x00E8;, I. Monteleone, R. Caruso, L. Franceschilli, P. Sileri, G. S. Sica, A. L. Gaspari, G. Del&#x00A0;Vecchio&#x00A0;Blanco, F. Pallone and G. Monteleone</dc:creator>
<dc:date>2012-09-01</dc:date>
<dc:identifier>doi:10.1042/CS20110556</dc:identifier>
<dc:title><![CDATA[2-Methoxy-5-amino-<i>N</i>-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms]]></dc:title>
<dc:publisher>Portland Press Ltd.</dc:publisher>
<prism:publicationDate>2012-09-01</prism:publicationDate>
<prism:section></prism:section>
</item>


<item rdf:about="http://www.clinsci.org/cs/123/0307/cs1230307.htm">
<title><![CDATA[B-type natriuretic peptide is an independent predictor of endothelial function in man]]></title>
<link>http://www.clinsci.org/cs/123/0307/cs1230307.htm</link>
<description><![CDATA[
<p>BNP (B-type natriuretic peptide) has been reported to be elevated in preclinical states of vascular damage. To elucidate the relationship between plasma BNP and endothelial function, we have investigated the relationship between BNP and endothelial function in a cohort of subjects comprising healthy subjects as well as at-risk subjects with cardiovascular risk factors. To also clarify the relative contribution of different biological pathways to the individual variation in endothelial function, we have examined the relationship between a panel of multiple biomarkers and endothelial function. A total of 70 subjects were studied (mean age, 58.1&#177;4.6&#160;years; 27% had a history of hypertension and 18% had a history of hypercholesterolaemia). Endothelium-dependent vasodilatation was evaluated by the invasive ACH (acetylcholine)-induced forearm vasodilatation technique. A panel of biomarkers of biological pathways was measured: BNP, haemostatic factors PAI-1 (plasminogen-activator inhibitor 1) and tPA (tissue plasminogen activator), inflammatory markers, including cytokines [hs-CRP (high sensitive C-reactive protein), IL (interleukin)-6, IL-8, IL-18, TNF&#945; (tumour necrosis factor &#945;) and MPO (myeloperoxidase] and soluble adhesion molecules [E-selectin and sCD40 (soluble CD40)]. The median BNP level in the study population was 26.9 pg/ml. Multivariate regression analyses show that age, the total cholesterol/HDL (high-density lipoprotein) ratio, glucose and BNP were independent predictors of endothelial function, and BNP remained an independent predictor (<i>P</i>=0.009) in a binary logistic regression analysis using FBF (forearm blood flow) as a dichotomous variable based on the median value. None of the other plasma biomarkers was independently related to ACH-mediated vasodilatation. In a strategy using several biomarkers to relate to endothelial function, plasma BNP was found to be an independent predictor of endothelial function as assessed by endothelium-dependent vasodilatation in response to ACH.</p>]]></description>
<dc:creator>M. Pauriah, F. Khan, T. K. Lim, D. H. Elder, V. Godfrey, G. Kennedy, J. J. F. Belch, N. A. Booth, A. D. Struthers and C. C. Lang</dc:creator>
<dc:date>2012-09-01</dc:date>
<dc:identifier>doi:10.1042/CS20110168</dc:identifier>
<dc:title><![CDATA[B-type natriuretic peptide is an independent predictor of endothelial function in man]]></dc:title>
<dc:publisher>Portland Press Ltd.</dc:publisher>
<prism:publicationDate>2012-09-01</prism:publicationDate>
<prism:section></prism:section>
</item>


<item rdf:about="http://www.clinsci.org/cs/123/0313/cs1230313.htm">
<title><![CDATA[High-intensity exercise attenuates postprandial lipaemia and markers of oxidative stress]]></title>
<link>http://www.clinsci.org/cs/123/0313/cs1230313.htm</link>
<description><![CDATA[
<p>Regular exercise can reduce the risk of CVD (cardiovascular disease). Although moderate-intensity exercise can attenuate postprandial TAG (triacylglycerol), high-intensity intermittent exercise might be a more effective method to improve health. We compared the effects of high-intensity intermittent exercise and 30&#160;min of brisk walking on postprandial TAG, soluble adhesion molecules and markers of oxidative stress. Nine men each completed three 2-day trials. On day 1, subjects rested (control), walked briskly for 30&#160;min (walking) or performed 5&#215;30&#160;s maximal sprints (high-intensity). On day 2, subjects consumed a high-fat meal for breakfast and 3&#160;h later for lunch. Blood samples were taken at various times and analysed for TAG, glucose, insulin, ICAM-1 (intracellular adhesion molecule-1), VCAM-1 (vascular adhesion molecule-1), TBARS (thiobarbituric acid- reactive substances), protein carbonyls and &#946;-hydroxybutyrate. On day 2 of the high-intensity trial, there was a lower (<i>P</i>&#60;0.05) incremental TAG AUC (area under the curve; 6.42&#177;2.24&#160;mmol/l per 7&#160;h) compared with the control trial (9.68&#177;4.77&#160;mmol/l per 7&#160;h) with no differences during day 2 of the walking trial (8.98&#177;2.84&#160;mmol/l per 7&#160;h). A trend (<i>P</i>=0.056) for a reduced total TAG AUC was also seen during the high-intensity trial (14.13&#177;2.83&#160;mmol/l per 7&#160;h) compared with control (17.18&#177;3.92&#160;mmol/l per 7&#160;h), walking showed no difference (16.33&#177;3.51&#160;mmol/l per 7&#160;h). On day 2 of the high-intensity trial plasma TBARS and protein carbonyls were also reduced (<i>P</i>&#60;0.05) when compared with the control and walking trials. In conclusion, high-intensity intermittent exercise attenuates postprandial TAG and markers of oxidative stress after the consumption of a high-fat meal.</p>]]></description>
<dc:creator>B. Gabriel, A. Ratkevicius, P. Gray, M. P. Frenneaux and S. R. Gray</dc:creator>
<dc:date>2012-09-01</dc:date>
<dc:identifier>doi:10.1042/CS20110600</dc:identifier>
<dc:title><![CDATA[High-intensity exercise attenuates postprandial lipaemia and markers of oxidative stress]]></dc:title>
<dc:publisher>Portland Press Ltd.</dc:publisher>
<prism:publicationDate>2012-09-01</prism:publicationDate>
<prism:section></prism:section>
</item>


<item rdf:about="http://www.clinsci.org/cs/123/0323/cs1230323.htm">
<title><![CDATA[Adenosine A2a receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats]]></title>
<link>http://www.clinsci.org/cs/123/0323/cs1230323.htm</link>
<description><![CDATA[
<p>NEFA (non-esterified 'free' fatty acid)-mediated lipotoxicity plays a critical role in the pathogenesis of NASH (non-alcoholic steatohepatitis). In the light of the growing need for new therapeutic options for NASH, we investigated the action of A<sub>2a</sub>R (adenosine A<sub>2a</sub> receptor) stimulation against lipotoxicity. The effects of the A<sub>2a</sub>R agonist CGS21680 [2-<i>p</i>-(2-carboxyethyl)phenethylamino-5&#8242;-<i>N</i>-ethylcarboxyamidoadenosine] were evaluated '<i>in vitro</i>' in liver cells exposed to SA (stearic acid) and '<i>in vivo</i>' in rats with NASH induced by 8&#160;weeks of feeding with an MCD diet (methionine/choline-deficient diet). In cultured hepatocytes, SA promoted apoptosis by inducing MKK4 (mitogen-activated protein kinase kinase 4)/SEK1 (stress-activated protein kinase/extracellular-signal-regulated kinase kinase-1) and JNK-1/2 (c-Jun N-terminal kinase-1/2) activation. CGS21680 addition prevented JNK-1/2 activation and reduced apoptosis without interfering with lipid accumulation. CGS21680 action required PI3K (phosphoinositide 3-kinase)/Akt-mediated block of MKK4/SEK1. Consistently, PI3K inhibition with wortmannin abolished the cytoprotective action of CGS21680 and reverted MKK4 inhibition. SA lipotoxicity was also prevented by transfecting HTC cells with a specific MKK4/SEK1 siRNA (small interfering RNA). In rats receiving the MCD diet, the development of NASH was associated with MKK4/SEK1 and JNK-1/2 activation. CGS21680 (0.5&#160;mg/kg of body weight, intraperitoneal) administration to MCD-fed rats prevented JNK-1/2 activation by acting on MKK4/SEK1. CGS21680 also effectively reduced NASH-associated ALT (alanine aminotransferase) release, hepatocyte apoptosis, liver inflammation and fibrosis without affecting hepatic steatosis. Taken together, these results demonstrate that, by inhibiting JNK-1/2, A<sub>2a</sub>R stimulation reduces lipotoxicity and ameliorates NASH, giving a rationale to investigate A<sub>2a</sub>R agonists as possible new therapeutic agents in preventing fatty liver progression to NASH.</p>]]></description>
<dc:creator>C. Imarisio, E. Alchera, S. Sutti, G. Valente, F. Boccafoschi, E. Albano and R. Carini</dc:creator>
<dc:date>2012-09-01</dc:date>
<dc:identifier>doi:10.1042/CS20110504</dc:identifier>
<dc:title><![CDATA[Adenosine A<sub>2a</sub> receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats]]></dc:title>
<dc:publisher>Portland Press Ltd.</dc:publisher>
<prism:publicationDate>2012-09-01</prism:publicationDate>
<prism:section></prism:section>
</item>



</rdf:RDF>

